Novaliq’s Eyesol Drug Development Process with a GMP-compliant Supply Chain is securing market supply for new and IP protected products.
Novaliq’s Eyesol Drug Development Process with proven processes and established regulatory pathway referencing to Novaliq’s already marketed products and secured Supply Chain helps
- to streamline drug development,
- to reduce cost and time for bringing products to the patient, and
- to increase success rate in the market.
The process enables a rapid pre-clinical prototyping and a fast, efficient pre-clinical and clinical development.